Ex Vivo Models for Oncology
Empower your cancer research with the world’s most highly annotated ex vivo tumor bank, providing the scalability of cell lines and the clinical applicability of PDO models. This unique collection includes 1,400+ rare TumorGraft3D cancer models and more than 100 primary blood cancer models, streamlining the development of breakthrough therapeutics.
- Preclinical Oncology CRO Services | Clinical Trial Specialty Testing
- Ex Vivo Models for Oncology
Expedite Preclinical Oncology & Immuno-Oncology Pipelines
Successful advancement of new drugs into clinical practice depends on reliable preclinical models. Having access to advanced, clinically relevant ex vivo models and assays for evaluating novel cancer therapeutics is essential. At Champions, our scientists have created a comprehensive suite of ex vivo assays, including the largest biobank of ex vivo blood cancer models, our proprietary TumorGraft3D platform for drug testing in multiclonal 3D-organoids, and a co-culture platform for preclinical screening of immuno-therapeutics.
Clinically Relevant Models
A diverse bank of ex vivo preclinical models that mirrors the oncology patient population
Scalable Screening Platform
Operational scalability of cell lines coupled with the clinical fidelity of PDO models
Multi-omic Characterization
Clinical annotations coupled with multi-omic molecular datasets and ex vivo responses
Your Oncology Research Partner
Delivering tailored consultations from scientists with Extensive Experience in Oncology
Screen relevant preclinical ex vivo models to advance your in vivo studies
Champions Oncology provides a comprehensive suite of ex vivo services, designed for evaluating new cancer therapies across all modalities. Our platforms screen the therapeutic potential of your treatments to maximize success in vivo.
- Cost-Effective & Scalable Screening Platform: Delivering high-quality results, for subsequent in vivo testing with confidence and reliable data.
- Flexibility of Endpoint: Choose from multiple endpoint analyses developed specifically for high throughput screening, giving you actionable insights.
- Robustly Characterized: Ex vivo models with full multi-omic characterization datasets, have also been evaluated for proliferation and tested with standards of care.
- Biological & Clinical Relevance: Models mirror the patient population's tumor heterogeneity & preserve key molecular and phenotypic features of patient tumors, including critical mutations like KRAS, kinases, and epigenetic targets.
Identify the Best Ex Vivo Platform for your Project
HEMATOLOGICAL VITROSCREEN
Test therapeutics in the largest bank of highly characterized primary, never-passaged hematological models from leukemia, lymphoma, & myeloma patients
TUMORGRAFT3D PLATFORM
Evaluate therapeutic efficacy in Champions' matrix-free, multiclonal 3D ex-vivo culture established from unique PDX models
CO-CULTURE ASSAYS
Assess the effect therapeutic agents have on cancer cells and the immune system in the tumor microenvironment
"Their innovative approach to modeling complex tumor environments has delivered clear and actionable data, facilitating more effective preclinical studies."
___________________________________________________
"We’ve been thoroughly impressed with the ex vivo platforms at Champions Oncology. The high quality results have provided critical insights into treatment mechanisms and efficacy, significantly advancing our research."
___________________________________________________
"The realistic tumor microenvironment provided by these models has allowed us to conduct more relevant studies, driving forward our drug development programs."
___________________________________________________
What are Ex Vivo Models ?
Ex vivo tumor models are generated from tumor tissues or cells from patients or animal models and used shortly after their collection to minimize the adaptation to culture conditions and selection processes that are typically observed in models grown in vitro. to study cancer outside the organism. Ex vivo models from solid tumors can be developed as two-dimensional (2D) cultures in adherent plates or as three-dimensional (3D) cultures in suspension in non-adherent plates in presence or absence of an extracellular matrix. Ex vivo models of hematopoietic malignancies are grown as cell suspensions from samples collected from blood or bone marrow.
What type of assays can be run with Ex Vivo models?
At Champions, we provide a range of ex vivo solutions tailored to diverse project needs:
- Hematological Vitro Screen: Our Ex Vivo Hematologic Model Screening platform uses primary patient samples to test the effectiveness and investigate the mechanisms of action of blood cancer therapies. It includes the largest collection of models for cancers such as Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphoblastic Leukemia (CLL), Mantle Cell Lymphoma (MCL), and Multiple Myeloma (MM).
- TumorGraft3D Platform: A 3D ex vivo drug testing platform using very low passage solid tumor 3D-organoids derived from patient-derived xenograft (PDX) models.
- Co-Culture Assays: An ex vivo platform featuring TumorGraft3D or hematological models, co-cultured with primary immune or stromal cells as needed for preclinical immuno-oncology and tumor-tissue microenvironment interaction studies. It supports testing of NK and T cell engagers, ADCC agents, BiTEs, immune checkpoint inhibitors, cancer vaccines, small molecules, gene therapy, cell therapy, and combinatorial therapy.
Why are ex vivo models important in drug discovery?
Ex vivo models are important experimental tools that bridge the gap between in vitro cell cultures and in vivo animal models, they help improve drug development by providing a more accurate representation of how a drug might perform by offering a more physiologically relevant substrate for evaluation of the efficacy of potential cancer therapies. Ex vivo models enable faster, cost-effective, and higher-throughput assessment of therapeutic agent’s efficacy or mechanism of action, and enable informed decision-making when transitioning into in vivo studies.
How can I start an ex vivo drug screening project with Champions?
There are many aspects to be considered when planning and executing a successful ex vivo study. Champions works with you every step of the way to ensure you select the best models to test your hypothesis and choose endpoints that will lead to unparalleled insights driving decision-making.